Jump to main content
eTG Complete
eTG Complete
Index
  1. Home
  2. Antibiotic
  3. Eye infections
  4. Periorbital (preseptal) and orbital (postseptal) cellulitis
  5. Intravenous therapy for periorbital (preseptal) cellulitis
  6. Patients at increased risk of MRSA infection
  • Antibiotic
    • Bartonella infections
    • Osteomyelitis
    • Septic arthritis of a native joint
    • Bone and joint infections other than osteomyelitis and native joint septic arthritis
    • Sepsis or septic shock associated with a bone or joint source
    • Directed therapy for native bone or joint infection
    • Brucellosis
    • Infective endocarditis
    • Cardiovascular system infections other than endocarditis
    • Central nervous system infections
    • Coronavirus disease 2019 (COVID-19)
    • Cryptococcosis
    • Cytomegalovirus (CMV) infection
    • Infectious diarrhoea
    • Ear, nose and throat infections
    • Eye infections
      • Blepharitis
      • Chalazion (meibomian cyst) and hordeolum (stye)
      • Conjunctivitis
      • Corneal abrasion and foreign bodies
      • Dacryocystitis
      • Endophthalmitis
      • Epiphora
      • Infectious keratitis
      • Periorbital (preseptal) and orbital (postseptal) cellulitis
        • Assessment of periorbital (preseptal) and orbital (postseptal) cellulitis
        • Approach to managing periorbital (preseptal) cellulitis
        • Oral therapy for patients with periorbital (preseptal) cellulitis
        • Intravenous therapy for periorbital (preseptal) cellulitis
          • Patients at low risk of MRSA infection
          • Patients at increased risk of MRSA infection
          • Patient review, and modification and duration of intravenous therapy for periorbital cellulitis
        • Approach to managing orbital (postseptal) cellulitis
        • Intravenous therapy for orbital (postseptal) cellulitis
        • Modification and duration of therapy for orbital (postseptal) cellulitis
        • References
    • Febrile neutropenia
    • Genital and sexually transmissible infections
    • Human immunodeficiency virus
    • Intra-abdominal infections
    • Leptospirosis
    • Lyme disease
    • Mediastinitis
    • Melioidosis
    • Mpox (monkeypox)
    • Nocardiosis
    • Nontuberculous mycobacterial infections
    • Oesophageal infections
    • Parasitic infections
    • Perinatal infections
    • Prevention of infection
    • Q fever
    • Pneumonia
    • Directed therapy for pneumonia
    • Respiratory tract infections other than pneumonia
    • Acute rheumatic fever
    • Rickettsial infections
    • Salivary gland infections
    • Sepsis and septic shock: Identification and initial management
    • Sepsis and septic shock: Empirical regimens
    • Directed therapy for bloodstream infections, including sepsis and septic shock
    • Skin and soft tissue infections
    • Traumatic wound infections
    • Urinary tract infections in adults
    • Urinary tract infections in children
    • Identifying resistant pathogens or Candida species
    • Principles of obtaining blood for culture
    • Principles of antimicrobial use
    • Antimicrobial stewardship (AMS)
    • Practical information on using antimicrobial drugs
    • Aminoglycoside use
    • Vancomycin use in adults
    • Vancomycin use in young infants and children
    • Monitoring antimicrobial blood concentrations
    • Ambulatory antimicrobial therapy
    • Antimicrobial hypersensitivity
    • Kidney impairment and antimicrobial dosing
    • Contact details for health departments and public health units
    • Amikacin initial dose calculator
    • Gentamicin initial dose calculator
    • Tobramycin initial dose calculator

Patients at increased risk of MRSA infection

For patients with periorbital cellulitis who are systemically unwell in whom orbital cellulitis has been excluded and who are at increased risk of MRSA infection, use:

vancomycin intravenously; see Intermittent vancomycin dosing for noncritically ill adults or Intermittent vancomycin dosing for children for initial dosing. See advice on patient review, and modification and duration of therapy. vancomycin vancomycin vancomycin

  • Contact us
  • Conditions of use and disclaimer
  • Privacy policy
  • Copyright permission
  • Support and FAQ

www.tg.org.au
All site content © Therapeutic Guidelines Limited 2020. Therapeutic Guidelines Limited, Ground Floor, 473 Victoria Street, West Melbourne, Victoria 3003, Australia © Therapeutic Guidelines Ltd (eTG August 2020)

Created: No created attribute found. Modified: No revised attribute found. (HW Diagnostics)